COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA.
作者信息
Krantz Matthew S, Phillips Elizabeth J
机构信息
Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, USA; Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, WA, Australia.
出版信息
Lancet Infect Dis. 2022 Jun;22(6):747-748. doi: 10.1016/S1473-3099(22)00123-2. Epub 2022 Mar 7.
Abstract
摘要
相似文献
1
COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA.
Lancet Infect Dis. 2022 Jun;22(6):747-748. doi: 10.1016/S1473-3099(22)00123-2. Epub 2022 Mar 7.
2
Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination.
Circ J. 2022 Mar 25;86(4):724. doi: 10.1253/circj.CJ-21-0840. Epub 2021 Dec 4.
3
Prior SARS-CoV-2 infection increases reactogenicity after SARS-COV-2 mRNA vaccine and could delay the administration of the vaccine based on timing of infection.
Infection. 2022 Jun;50(3):791-793. doi: 10.1007/s15010-021-01729-z. Epub 2021 Dec 2.
4
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
Mult Scler Relat Disord. 2022 Mar;59:103690. doi: 10.1016/j.msard.2022.103690. Epub 2022 Feb 13.
5
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
Trials. 2022 Jun 16;23(1):498. doi: 10.1186/s13063-022-06345-2.
6
Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
Platelets. 2022 May 19;33(4):652-653. doi: 10.1080/09537104.2022.2044463. Epub 2022 Feb 28.
7
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
8
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine.
Lancet Microbe. 2022 Aug;3(8):e561. doi: 10.1016/S2666-5247(22)00150-1. Epub 2022 May 31.
9
Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
JAMA Netw Open. 2022 Aug 1;5(8):e2226236. doi: 10.1001/jamanetworkopen.2022.26236.
10
Urticarial vasculitis triggered by SARS-CoV-2 vaccine (mRNA vaccine).
J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e743-e744. doi: 10.1111/jdv.18253. Epub 2022 Jun 3.
引用本文的文献
1
Safety of the bivalent COVID-19 mRNA booster vaccination among persons aged over 18 years in the Republic of Korea.
Osong Public Health Res Perspect. 2024 Dec;15(6):542-549. doi: 10.24171/j.phrp.2024.0194. Epub 2024 Oct 29.
本文引用的文献
1
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.
Lancet Infect Dis. 2022 Jun;22(6):802-812. doi: 10.1016/S1473-3099(22)00054-8. Epub 2022 Mar 7.
2
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
Lancet Infect Dis. 2021 Jul;21(7):939-949. doi: 10.1016/S1473-3099(21)00224-3. Epub 2021 Apr 27.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
4
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
5
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).
Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22.
Zotero 插件